Joint Effort

Welcome to the JE Blog – just another blog …

Pharmaceutical companies in the news – Taxpayers Against Fraud

pillsThe pharmaceutical industry continues to lead the way in Tax Fraud cases!  Paying million dollar fines and having teams of lawyers  defending their actions have just become part of everyday business.  The cost is not a big deal, it is passed on to you the consumer…   These companies are the biggest and best in the business!  They are the ones that flood your every TV hour with thousands of ads marketing new illnesses and treatments.  Please note I referenced “treatments”, they don’t want you be be cured, that would not be good for business …   Be an informed consumer.  Frequent the TAF web-site often to see who’s at the top of the list!  (LINK)

The latest News:

Forest Laboratoris charged with defrauding the goverment
DoJ has charged Forest Laboratories with defrauding the government by illegally marketing the antidepressants Celexa and Lexapro for unapproved use in children and teenagers. Prosecutors charge former top executives at Forest with concealing a clinical study that showed that Celexa and Lexapro were not effective in children and might even pose risks, including causing some to become suicidal.

Amgen -biotechnology company -Massive Amgen Fraud Case
An unidentified whistleblower has filed a False Claims Act case against Amgen, the biotechnology company which makes arthritis and psoriasis drug Enbrel, and anti-anemia drug Aranesp. Amerisource-Bergen and online health-information provider WebMD Health Corp are also named. The case came out from under seal at a judge’s directive, and DoJ is still deciding if it will join. The case involves off-label marketing, kickbacks and Medicaid best price violations.

Johnson & Johnson and Scios are alleged in off-label marketing
The U.S. Justice Department has joined two whistleblower lawsuits alleging that Johnson & Johnson and Scios engaged in off-label marketing of the cardiac drug Natrecor.

GlaxoSmithKline has reserved $400 million to settle off-label and kick back chargesGlaxo’s $400 Million Reserve
GlaxoSmithKline has reserved $400 million to settle off-label and kick back charges related to “several products” sold from 1997 to 2004, including the antidepressant Wellbutrin. Glaxo said the reserve “reflects the current status of the [DoJ] investigation.”

The Top 20 Cases:   HEALTH-CARE FRAUD – A Billion Dollar Business!   (LINK)

Kindle – Amazing new Wireless Reading Device

Advertisements

Written by jointefforthost

March 16, 2009 at 2:05 am

%d bloggers like this: